US equities
|
NVDA
$204.64
▼-4.22%
INTC
$65.76
▼-28.58%
MU
$884.74
▼-5.30%
AMZN
$240.35
▼-1.41%
AAPL
$344.63
▼-1.23%
SNDK
$1,150.89
▼-13.47%
AMD
$504.80
▼-10.88%
MSFT
$521.91
▼-1.55%
NVDA
$204.64
▼-4.22%
INTC
$65.76
▼-28.58%
MU
$884.74
▼-5.30%
AMZN
$240.35
▼-1.41%
AAPL
$344.63
▼-1.23%
SNDK
$1,150.89
▼-13.47%
AMD
$504.80
▼-10.88%
MSFT
$521.91
▼-1.55%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Tools
My watchlist
My portfolio
Recent quotes
Pharmather Holdings Ltd
(OP:
PHRRF
)
0.0379
-0.0020 (-5.01%)
Delayed Quote
Updated: 3:15 PM EDT, Oct 30, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Pharmather Holdings Ltd
< Previous
1
2
3
4
5
Next >
Psyched: Protesters At DEA HQ Demand Access To Psychedelics, Connecticut Approves Budget Bill With MDMA & Psilocybin Programs
↗
May 10, 2022
Psychedelics policy action took center stage this week.
Via
Benzinga
Pharmather Lands US Patent To Formulate, Produce Ketamine With This New Process
↗
May 05, 2022
The U.S. Patent and Trademark Office has granted Pharmather Holdings Ltd. (OTCQB: PHRRF) a patent for a ketamine production process.
Via
Benzinga
Psyched: Elon Musk Praises Psychedelics Over Antidepressants, Field Trip To Split In Two, Colorado MDMA Bill Moves Forward
↗
May 02, 2022
The world’s richest man gave another public nod to psychedelics medicine in favor of traditional mental health solutions.
Via
Benzinga
Pharmather Reports Improved Q3 Results, Continues Ketamine Trials For Epilepsy
↗
April 26, 2022
Pharmather Holdings Ltd. (OTCQB: PHRRF) reported financial results for its third quarter ended February 28, 2022.
Via
Benzinga
Ketamine Could Help Treat Parkinson's Disease, Study Finds
↗
March 24, 2022
PharmaTher Holdings Ltd. (OTCQB: PHRRF) announced positive results from a clinical study of ketamine for the treatment of ...
Via
Benzinga
Psychedelic Medicine Co. PharmaTher Provides Update On Pipeline And Milestones For 2022
↗
January 25, 2022
This article was originally published on Micr...
Via
Benzinga
FDA Approves PharmaTher's Phase 2 Trial For Ketamine ALS Treatment
↗
January 12, 2022
PharmaTher Holdings Ltd (OTCQB: PHRRF) (CSE: PHRM), is a Canadian company focused on the development and commercialization of medicines derived from ketamine. PharmaTher announced...
Via
Benzinga
Psyched: Detroit Decriminalizes Psychedelics, Compass To Study Psilocybin For PTSD, Filaments Gets First-Ever FDA Approval
↗
November 08, 2021
Detroit Decriminalizes Psychedelics
Via
Benzinga
Psyched: Seattle Decriminalizes Psychedelics, Psilocybin Increases Emotions From Music, Novamind's Palliative Care Program
↗
October 11, 2021
The Week In Psychedelics
Via
Benzinga
Psyched: Elon Musk Discusses Psychedelics, Delix Raises $70M, MindCure To Study MDMA In Female Sexual Dysfunction
↗
October 04, 2021
The Week In Psychedelics:
Via
Benzinga
Psyched: The 50 Publicly-listed Psychedelics Companies, Atai's New Subsidiary, PharmaTher Gets New Orphan Drug Designation
↗
October 18, 2021
The Week In Psychedelics
Via
Benzinga
Senate Bill Decriminalizing Psychedelics Could Help Reverse Some “War on Drugs” Impacts
September 22, 2021
Via
FinancialNewsMedia
These OTC Securities Had the Most Trading Activity in June
↗
July 20, 2021
Photo by Cris Ovalle on Unsplash OTC Markets trading volume was still led by cryptocurrencies and cannabis for the month of June, but many other securities shined comparatively as...
Via
Benzinga
Topics
Cannabis
There Are Now 50 Psychedelics Companies Listed In The U.S. - Here They Are
↗
October 13, 2021
Just two years ago, the psychedelics sector was a small research space reserved for academics and extremely forward-thinking investors. S...
Via
Benzinga
How To Invest In "Magic Mushrooms" (Psychedelics)
↗
July 09, 2021
A look at psychedelics as stock market investment opportunities and identifying alternative strategies on how to invest.
Via
Talk Markets
Psyched: GH Research Debuts on Nasdaq, Compass Reaches Psilocybin Research Milestone, Maxim Gives BUY Rating to 10 Psychedelics Companies
↗
July 02, 2021
Irish 5-MeO-DMT Company GH Research Debuts On Nasdaq GH Research, a Dublin-based company studying the potential o...
Via
Benzinga
Maxim Group Gives Buy Rating To 10 Psychedelic Stocks: Compass, MindMed, Cybin, Field Trip And More
↗
June 30, 2021
Institutional analysts are taking a liking to the industry ...
Via
Benzinga
Psyched: MindMed To Begin Mescaline Trials and Deepak Chopra Partnership, Seelos And Cybin Advance Clinical Research
↗
May 24, 2021
MindMed’s News Spree: Mescaline Trials, Chopra Foundation Partnership and LSD Research MindMed (NASDAQ:
Via
Benzinga
Psyched: MindMed, Atai Head For Nasdaq, Psychedelics Search Platforms Grow, Champignon Brands Resumes Trading
↗
April 26, 2021
Two of the most highly funded companies in the psychedelics space announced plans last week to list on the Nasdaq exchange. Months after ...
Via
Benzinga
Market For Psychedelic Drugs Expected to Reach $6.9 Billion By 2027
April 14, 2021
Via
FinancialNewsMedia
< Previous
1
2
3
4
5
Next >
